Pharmacogenomics Pioneer HairDX Names David Teckman President and Boss .

Kasey Cantu

20 August 2008

HairDX focuses on testing and genetic research of skin disorders and hair biology. Teckman is a flavored executive with over 30-years experience in several facets of healthcare.

He was lately President and Manager of Sutura, Inc ( SUTU ) a medical device manufacturer in Orange Country, California where he led a successful turnaround effort. He went to Sutura after serving as Director of Whitebox aides, a $4 bn. hedge fund based in Minneapolis, MN. He is now Manager of the Board of InstyMeds, a Minneapolis based supplier of automated prescription dispensing solutions for acute care settings.

Formerly , Teckman was President and Boss man of Vivius, a supplier of personalized health insurance solutions, President of Disc Systems, a doctor practice management software company, Senior VP, of Computers Health Systems, a drugstore benefit management company, Executive Director of Equior Health Plans and Countrywide Sales executive of Infomed Company . Teckman is a graduate of Miami Varsity ( Oxford, OH ) with a Bachelors Degree in Business Administration. Andy Goren, HairDX previous Chairperson is moving to the job of Boss man Co-Founder. "By bringing in an industry vet like David Teckman, HairDX is balanced to progress as a pioneer and leader in pharmacogenomics and healthcare research and development" related Goren. "The wedding of genetic testing and pharmacological solutions is an example of the subsequent new and engaging opportunities in healthcare" claimed Teckman. "Like several conditions, hair loss can be determined thru early screening and with a consultant preventative actions can be taken. I am pleased to have the chance to join the HairDX team." earlier in the year, HairDX became the 1st company to market genetic tests that forecast an individual's risk for the male or female versions of Androgenetic Alopecia ( Hair Loss ). The test is free in the States thru qualified consultants. HairDX uses a CLIA certified laboratory ( Clinical Laboratory Improvement Amendments ) to perform the genetic research, offering doctors a robust screening test for Androgenetic Alopecia before any plain evidence of hair loss. The HairDX test results can help a consultant in selecting a course of action as to maintain a patient's hair. HairDX markets the 1st genetic test for male and female hair loss. The company is dedicated to the study and development of new prescription based therapies tailored to an individual's genetic make up.